Business Context and Reporting Period
This Form 8-K Current Report was filed by OptimizeRx Corporation (OPRX) on December 23, 2024, regarding events occurring on December 23, 2024, and effective December 31, 2024. The filing addresses significant changes in executive leadership and the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- CEO Departure: William J. Febbo is stepping down as Chief Executive Officer and Board Member effective December 31, 2024, to pursue other opportunities.
- Interim Appointment: Stephen Silvestro, the current President, has been appointed Interim CEO and Interim Principal Executive Officer effective December 31, 2024.
- Search for Successor: The Board has retained a search firm to identify a permanent CEO candidate.
- Transition Services: Mr. Febbo will provide transition advisory services from January 1, 2025, through March 31, 2025.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or specific risk factors beyond the inherent uncertainty of a leadership transition. Management commentary is limited to the announcement of the search for a permanent CEO and the expectation of entering into a separation and advisory agreement with Mr. Febbo, the details of which are not yet finalized.
Investor Verification Checklist
- Verify the terms of the separation and advisory agreement with William J. Febbo once filed in a future SEC report.
- Monitor the timeline for the appointment of a permanent CEO following the interim period.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Confirm if any additional compensation will be awarded to Stephen Silvestro for his interim role, as this has not yet been determined.